Latest Filings

Issuer Activity

Overview :: CVS Health Corp (N:CVS) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for CVS
USD 103.870 -0.300 (-0.288%)
NYSE Delayed 15 minutes
Feb 27 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
104.520 104.480 26.15 3,808,864 116,880.00
1-Day Low 52-Week Low Yield Avg. Volume  
103.610 71.690 1.3% NYSE  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:27pm ET February 27th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 20/15 Feb 19/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -460 $102.62
Feb 20/15 Feb 18/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -339 $104.10
Feb 10/15 Feb 7/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -259 $100.61
Feb 10/15 Feb 7/15 Joyner J. David Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -263 $100.61
Jan 23/15 Jan 21/15 Bracken Richard M Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 703 $99.50
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -86,487  
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Common Stock S - Open market or private sale -86,487 $95.31
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 86,487 $41.17
Jan 6/15 Jan 5/15 Merlo Larry J Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -144,144  
Jan 6/15 Jan 5/15 Merlo Larry J Direct Ownership Common Stock S - Open market or private sale -144,144 $94.30
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for CVS within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:27pm ET February 27th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 20/15 Feb 19/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -460 $102.62
Feb 20/15 Feb 18/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -339 $104.10
Feb 10/15 Feb 7/15 Boratto Eva C Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -259 $100.61
Feb 10/15 Feb 7/15 Joyner J. David Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -263 $100.61
Feb 10/15 Aug 22/14 Denton David M Direct Ownership Common Stock Form 5 : Annual Statement of Beneficial Ownership of Securities -380 $79.24
Jan 23/15 Jan 21/15 Bracken Richard M Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 703 $99.50
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Stock Option M - Exercise or conversion exempt under rule 16b-3 -86,487  
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Common Stock S - Open market or private sale -86,487 $95.31
Jan 8/15 Jan 7/15 Roberts Jonathan C Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 86,487 $41.17
Jan 8/15 Aug 22/14 Roberts Jonathan C Direct Ownership Common Stock G - Gift -127 $79.24
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
David Wyatt Dorman
Independent Chairman of the Board
Jonathan C. Roberts
Executive Vice President; President of CVS Caremark
Larry J. Merlo
President, Chief Executive Officer, Director
David M. Denton
Chief Financial Officer, Executive Vice President
Lisa G. Bisaccia
Chief Human Resource Officer, Senior Vice President
Thomas M. Moriarty
Executive Vice President, General Counsel
Troyen A. Brennan
Executive Vice President, Chief Medical Officer
Helena B. Foulkes
Executive Vice President, President of CVS - Pharmacy
J. David Joyner
Executive Vice President
Per G. H. Lofberg
Executive Vice President
   
Company Contact
Address: 1 Cvs Dr
WOONSOCKET RI 02895-6146
Tel: 1-800-2010938
Website: cvshealth.com
IR: See website
Business Overview
CVS Health Corporation, formerly CVS Caremark Corporation, is a pharmacy healthcare provider in the United States. The Company has three business segments: Pharmacy Services, Retail Pharmacy and Corporate. Pharmacy Services provides pharmacy benefit management (PBM) services, including plan design and administration, formulary management, discounted drug purchase arrangements, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Pharmacy Services business operates under the Caremark, CarePlus CVS/pharmacy, CVS/caremarkTM, CVS/specialtyTM, RxAmerica, Accordant, SilverScript, Novologix and Coram names. As of September 30, 2014, the Retail Pharmacy Segment includes 7,779 retail drugstores, online retail pharmacy websites, CVS.com and Onofre.com.br, 17 onsite pharmacy stores and retail healthcare clinics.
Financial Overview
For the fiscal year ended 31 December 2014, CVS Health Corp revenues increased 10% to $139.37B. Net income before extraordinary items increased 1% to $4.65B. Revenues reflect Pharmacy Services Segment increase of 16% to $88.44B, Retail Pharmacy Segment increase of 3% to $67.8B, Comp. Store Sales (Growth - %) - Pharmay increase of 85% to 4.8%, Retail Sales-Retail Pharmacy increase of 3% to $67.8B.
Employees: 137,800 as of Dec 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $127,320M as of Dec 31, 2014
Annual revenue (TTM): $139,367M as of Dec 31, 2014
EBITDA (TTM): $10,730M as of Dec 31, 2014
Net annual income (TTM): $4,645M as of Dec 31, 2014
Free cash flow (TTM): $4,713M as of Dec 31, 2014
Net Debt Last Fiscal Year: $10,440M as of Dec 31, 2014
Shares outstanding: 1,125,252,739 as of Feb 3, 2015
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
McKesson (N:MCK)
Cardinal Health (N:CAH)
Prestige Brands Holdings (N:PBH)